05.06.26 -- Enabling Next-Generation Modalities Through Integrated Analytical Process Expertise

Antibody–drug conjugates are complex biopharmaceuticals that link monoclonal antibodies to potent cytotoxic payloads. Their integrated design creates manufacturing and analytical challenges. Highly sensitive detection methods and flexible, scalable bioconjugation platforms are essential to ensure safety, quality, and efficient production.

This presentation addresses the critical need for high-throughput, reliable analytical development strategies that support the rapid progression of multispecific antibody candidates toward expedited Investigational New Drug (IND) applications and early clinical success.

A next-generation IVT platform addresses key mRNA manufacturing challenges through data-driven optimization and enzyme engineering. This approach enables consistent, high-quality production at various scales while reducing costs and supporting broader clinical and commercial adoption of mRNA therapeutics.